NO953182D0 - Farmasöytisk preparat for topisk administrering av antigener og/eller vaksiner til pattedyr via en slimhinnemembran - Google Patents

Farmasöytisk preparat for topisk administrering av antigener og/eller vaksiner til pattedyr via en slimhinnemembran

Info

Publication number
NO953182D0
NO953182D0 NO953182A NO953182A NO953182D0 NO 953182 D0 NO953182 D0 NO 953182D0 NO 953182 A NO953182 A NO 953182A NO 953182 A NO953182 A NO 953182A NO 953182 D0 NO953182 D0 NO 953182D0
Authority
NO
Norway
Prior art keywords
pct
vaccines
antigens
topical administration
pharmaceutical preparation
Prior art date
Application number
NO953182A
Other languages
English (en)
Other versions
NO312057B1 (no
NO953182L (no
Inventor
Sveinbjoern Gizurarson
Iver Heron
Original Assignee
Lyfjathroun H F
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyfjathroun H F, Statens Seruminstitut filed Critical Lyfjathroun H F
Publication of NO953182D0 publication Critical patent/NO953182D0/no
Publication of NO953182L publication Critical patent/NO953182L/no
Publication of NO312057B1 publication Critical patent/NO312057B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19953182A 1993-02-15 1995-08-14 Farmasöytisk preparat for topisk administrering av antigener og/eller vaksiner til pattedyr via en slimhinnemembran, samtanvendelse av adjuvant NO312057B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK93170A DK17093D0 (da) 1993-02-15 1993-02-15 Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
PCT/DK1994/000062 WO1994017827A1 (en) 1993-02-15 1994-02-14 A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane

Publications (3)

Publication Number Publication Date
NO953182D0 true NO953182D0 (no) 1995-08-14
NO953182L NO953182L (no) 1995-10-12
NO312057B1 NO312057B1 (no) 2002-03-11

Family

ID=8090567

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19953182A NO312057B1 (no) 1993-02-15 1995-08-14 Farmasöytisk preparat for topisk administrering av antigener og/eller vaksiner til pattedyr via en slimhinnemembran, samtanvendelse av adjuvant

Country Status (14)

Country Link
US (1) US5942237A (no)
EP (1) EP0682528B1 (no)
JP (1) JPH09508614A (no)
AT (1) ATE195077T1 (no)
AU (1) AU668290B2 (no)
CA (1) CA2156084A1 (no)
DE (1) DE69425427T2 (no)
DK (2) DK17093D0 (no)
ES (1) ES2150982T3 (no)
GR (1) GR3034727T3 (no)
NO (1) NO312057B1 (no)
OA (1) OA10564A (no)
PT (1) PT682528E (no)
WO (1) WO1994017827A1 (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316745D0 (en) * 1993-08-12 1993-09-29 Medeva Holdings Bv Vaccine compositions
ATE226829T1 (de) * 1996-01-25 2002-11-15 Profylakse Aps Pharmazeutische zusammensetzung, enthaltend serum-amyloid p-komponenten, zur prophylaxe und therapie von viralen infektionen sowie kit zur detektionvon komplexen zwischen solchen zusammensetzungen und viralen komponenten
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
IL138000A0 (en) * 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
US7229621B2 (en) * 1998-10-20 2007-06-12 Torrey Pines Institute For Molecular Studies Method to enhance the immunogenicity of an antigen
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
EP1034792A1 (en) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
ES2293923T3 (es) * 1999-09-24 2008-04-01 Glaxosmithkline Biologicals S.A. Vacuna intranasal contra el virus influenza.
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
AU2002367976B2 (en) * 2001-06-05 2007-06-21 The Regents Of The University Of Michigan Nanoemulsion vaccines
CA2457595A1 (en) * 2001-08-16 2003-02-27 Lyfjathroun H.F., Biopharmaceuticals A method of producing antibodies ex-vivo
KR100406503B1 (ko) * 2001-09-25 2003-11-19 한국과학기술연구원 폐렴구균성 표면 접착단백질의 가용화용 조성물, 가용화용액상제형, 및 가용화용 분말제형, 이들 각각의 제조방법및 백신
CN1642576A (zh) * 2002-02-25 2005-07-20 药物发展有限公司 吸收增强剂
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
AU2002352938B8 (en) * 2002-11-26 2009-10-08 The University Of Chicago Materials and methods for preventing and treating microbe-mediated epithelial disorders
US20070184058A1 (en) * 2003-02-27 2007-08-09 Yaron Ilan Glucocerebroside treatment of pulmonary or respiratory diseases or disorders
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
KR20070044805A (ko) 2004-04-15 2007-04-30 키아스마, 인코포레이티드 생물학적 장벽 투과를 촉진시킬 수 있는 조성물
CA2596920C (en) * 2005-01-28 2015-05-05 North-West University Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
WO2006110699A1 (en) * 2005-04-11 2006-10-19 Nanobio Corporation Quaternary ammonium halides for treatment of infectious conditions
CA2618974C (en) * 2005-08-09 2014-01-28 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
US9839685B2 (en) * 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US20080038295A1 (en) * 2006-04-13 2008-02-14 Regents Of The University Of Michigan Compositions and methods for orthopox virus vaccination
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
JP5275047B2 (ja) * 2007-01-31 2013-08-28 久光製薬株式会社 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
US20090093019A1 (en) * 2007-04-27 2009-04-09 Phelps Jamie P Production and in vivo assembly of soluble recombinant icosahedral virus-like particles
EP2293813A4 (en) * 2008-05-23 2012-07-11 Univ Michigan NANOEMULSION VACCINES
NZ591810A (en) 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
US20100316673A1 (en) * 2009-06-16 2010-12-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University CMV glycoproteins and recombinant vectors
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
ES2744454T3 (es) 2013-10-31 2020-02-25 Hisamitsu Pharmaceutical Co Composición de adyuvante
WO2015182735A1 (ja) * 2014-05-30 2015-12-03 キリン株式会社 乳酸菌免疫賦活作用増強組成物及び乳酸菌免疫賦活作用増強方法
CA2975599A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN111721937B (zh) * 2019-03-29 2023-04-07 北京九强生物技术股份有限公司 人附睾蛋白4免疫比浊试剂盒
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171125A (en) * 1966-06-08 1969-11-19 Glaxo Lab Ltd Improvements in or relating to Injectable Preparations
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
DE3446515A1 (de) * 1984-12-20 1986-06-26 Behringwerke Ag, 3550 Marburg Oeladjuvierte vaccine und verfahren zu ihrer herstellung
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
NL9000207A (no) * 1990-01-29 1991-08-16 Duphar Int Res
GB9018690D0 (en) * 1990-08-24 1990-10-10 Wellcome Found Vaccines
ES2136620T3 (es) * 1991-04-19 1999-12-01 Lds Technologies Inc Formulaciones de microemulsiones convertibles.
CZ42894A3 (en) * 1991-08-26 1995-02-15 Scripps Research Inst Peptides inducing cytotoxic response of t lymphocytes to hepatitis b virus
CA2083553A1 (en) * 1991-11-25 1993-05-26 Kuniharu Seki Immunogen composition

Also Published As

Publication number Publication date
GR3034727T3 (en) 2001-01-31
WO1994017827A1 (en) 1994-08-18
ES2150982T3 (es) 2000-12-16
DE69425427T2 (de) 2001-02-08
PT682528E (pt) 2001-01-31
AU6106594A (en) 1994-08-29
NO312057B1 (no) 2002-03-11
DK17093D0 (da) 1993-02-15
NO953182L (no) 1995-10-12
CA2156084A1 (en) 1994-08-18
EP0682528B1 (en) 2000-08-02
DE69425427D1 (de) 2000-09-07
AU668290B2 (en) 1996-04-26
OA10564A (en) 2002-06-20
JPH09508614A (ja) 1997-09-02
DK0682528T3 (da) 2000-12-27
US5942237A (en) 1999-08-24
ATE195077T1 (de) 2000-08-15
EP0682528A1 (en) 1995-11-22

Similar Documents

Publication Publication Date Title
NO953182L (no) Farmasöytisk preparat for topisk administrering av antigener og/eller vaksiner til pattedyr via en slimhinnemembran
KR950700758A (ko) 비-이온성 계면활성제 소포를 함유하는 백신(Vaccines containing non ionic surfactant vesicles)
ATE250937T1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
ITMI922699A1 (it) Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
NO20005051L (no) Adjuvantsammensetninger
ES8403024A1 (es) Un procedimiento para la fabricacion de un preparado farmaceutico para uso externo, a base de un compuesto no esteroi- dico.
ITMI922192A1 (it) Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
DK2353608T3 (da) Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
AU4346996A (en) Pharmaceutical aerosol containing at least one sugar
FI953442A (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
ES2125679T3 (es) Sistema transdermico de administracion simultanea de varios principios activos.
CO4520286A1 (es) Procedimiento para preparar clorhidrato de 1-(2 -desoxi-2 , 2 -difluoro-d-ribofuranosil)-4-aminopirimidin-2-ona
UA27848C2 (uk) Лікарська форма, що перорально вводиться, для лікування центральних станів дефіциту допаміну
IE894049L (en) Therapeutically active substituted benzimidazole and process¹for its preparation
PE11399A1 (es) Combinacion de loratadina y un descongestionante para el tratamiento del asma
NO951982D0 (no) Mucosal tilförsel av pneumokokkiske antigener
NO963634D0 (no) Antihostepreparat inneholdende et antihostemiddel og benzydamin
FR2682114B1 (fr) Vaccin de sous-unite contre les infections a neisseria meningitidis et sous-unites correspondantes a l'etat purifie.
ATE256134T1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
MX9302272A (es) Retinoides solubles en agua.
WO1996039113A3 (en) Oral administration of pneumococcal antigens
AU2471201A (en) Plant lectins as mucosal adjuvants
NO943251L (no) Oral vaksine
TH12267A (th) สารผสมชนิดเจลซึ่งควบคุมน้ำมันได้ดีขึ้น
IT8819669A0 (it) 2_0_acetil_1,3bis(difosforil_colina)_glicerolo procedimento per la sua preparazione e suo uso terapeutico.